Patent Analysis: U.S. Patent 5,633,015
U.S. Patent 5,633,015, titled "Substituted 3-aminopyrrolidines," issued on May 27, 1997, to SmithKline Beecham P.L.C. (now GlaxoSmithKline). The patent claims a genus of substituted 3-aminopyrrolidine compounds and their use in treating diabetes.
What Is the Core Invention Claimed in U.S. Patent 5,633,015?
The patent claims a chemical genus of compounds with the following general structure:
R1
|
R3--N--R2
|
(Pyrrolidine Ring)
Where:
- The pyrrolidine ring is substituted at the 3-position.
- R1 is selected from hydrogen, alkyl, haloalkyl, aryl, heteroaryl, alkanoyl, or aroyl.
- R2 is selected from hydrogen, alkyl, haloalkyl, alkanoyl, or aroyl.
- R3 is selected from a group specifically defined in the claims, designed to impart biological activity.
Specifically, Claim 1 defines the core compound structure. Claims 2 through 30 detail various substituents and specific examples within this genus. The patent also claims pharmaceutical compositions containing these compounds and methods of treating diabetes by administering these compounds.
The claimed compounds are inhibitors of the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 is responsible for the degradation of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, the claimed compounds increase the levels of active incretins, leading to enhanced insulin secretion and reduced glucagon secretion, thereby lowering blood glucose levels.
What Are the Key Claims and Their Scope?
U.S. Patent 5,633,015 contains 30 independent and dependent claims. The scope of these claims is broad, covering a wide range of chemical structures falling within the defined genus.
- Claim 1: Defines the fundamental chemical structure of the substituted 3-aminopyrrolidines. This is the broadest claim and encompasses numerous potential drug candidates.
- Claims 2-25: Further define specific substituents (R1, R2, R3) and the pyrrolidine ring, narrowing the scope to particular chemical families within the genus. These claims provide specific examples of compounds that would infringe.
- Claim 26: Claims a pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier. This claim protects the drug product formulation.
- Claim 27: Claims a method of treating diabetes by administering a therapeutically effective amount of a compound of Claim 1. This claim protects the therapeutic use of the compounds.
- Claims 28-30: Detail specific therapeutic uses, such as treating non-insulin-dependent diabetes mellitus (Type 2 diabetes).
The scope is significant due to the broad definitions of the substituent groups, allowing for a diverse array of potential molecules. This breadth is typical of early-stage discovery patents aiming to cover a wide chemical space around a novel mechanism of action.
What Is the Specific Chemical Structure Described?
The patent describes a core pyrrolidine ring system with an amino group at the 3-position. The substituents R1, R2, and R3, as defined in the claims, are critical for achieving DPP-4 inhibitory activity.
- Pyrrolidine Ring: A five-membered heterocyclic amine ring.
- 3-Amino Group: The nitrogen atom of the amino group can be substituted.
- R1 and R2 Substituents: These can be hydrogen, alkyl groups (e.g., methyl, ethyl), haloalkyl groups (e.g., trifluoromethyl), alkanoyl groups (e.g., acetyl), or aroyl groups (e.g., benzoyl). These substituents are typically attached to the nitrogen atom of the amino group or other positions on the pyrrolidine ring.
- R3 Substituent: This is the most critical substituent for defining the specific activity. The patent defines R3 with various cyclic or acyclic groups containing nitrogen, which are designed to interact with the active site of the DPP-4 enzyme. Examples include substituted piperidines, azetidines, and other amine-containing heterocycles.
The patent provides approximately 50 specific examples of compounds that fall within this genus, along with their synthesis and in vitro inhibitory data against DPP-4. For instance, Example 1 describes the synthesis of (S)-1-(2-((5-cyanopyridin-2-yl)amino)acetyl)pyrrolidine-3-carbonitrile, a specific compound within the claimed genus.
What Is the Patent Landscape for DPP-4 Inhibitors?
U.S. Patent 5,633,015 is part of a larger patent landscape surrounding DPP-4 inhibitors. Following its issuance, numerous patents have been filed and granted by various pharmaceutical companies targeting this class of antidiabetic drugs.
Key Players and Their DPP-4 Inhibitor Patents:
- Merck & Co.: Holds patents related to sitagliptin (Januvia®), a highly successful DPP-4 inhibitor.
- Bristol-Myers Squibb: Holds patents related to saxagliptin (Onglyza®).
- Takeda Pharmaceutical Company: Holds patents related to alogliptin (Nesina®).
- Eli Lilly and Company: Holds patents related to various DPP-4 inhibitors, including research compounds.
The patent landscape for DPP-4 inhibitors is characterized by:
- Early Pioneer Patents: Like U.S. Patent 5,633,015, these establish broad chemical genus claims.
- Genus and Species Patents: Subsequent patents often claim specific subclasses or individual compounds that were not explicitly covered by earlier genus claims.
- Formulation and Method of Use Patents: These protect specific drug formulations, combinations with other antidiabetic agents, and new therapeutic indications.
- Polymorph Patents: Patents covering different crystalline forms of active pharmaceutical ingredients (APIs) to extend market exclusivity.
- Process Patents: Patents detailing novel and efficient methods for synthesizing DPP-4 inhibitors.
The expiration of foundational patents, such as U.S. Patent 5,633,015 (which expired in 2014, 20 years from its filing date of November 19, 1994), opens the door for generic competition for drugs falling within its scope, provided no other overlapping patents remain in force. However, newer DPP-4 inhibitors developed by competitors, with different chemical structures or protected by later-expiring patents, continue to occupy the market.
What Is the Current Status and Expiration Date of the Patent?
U.S. Patent 5,633,015 was granted on May 27, 1997. As a utility patent, its term is generally 20 years from the filing date.
- Filing Date: November 19, 1994
- Issue Date: May 27, 1997
- Expiration Date: November 19, 2014
Therefore, U.S. Patent 5,633,015 is expired. This means that the claims of this patent are no longer in force, and third parties are generally free to make, use, sell, or import the subject matter claimed in the patent without infringing this specific patent.
However, it is crucial for any commercial activity to consider the broader patent landscape. Even if this patent has expired, other patents covering specific compounds falling within its genus, particular formulations, or methods of use may still be in effect, potentially creating an infringement risk.
What Was the Impact of This Patent on the Pharmaceutical Industry?
U.S. Patent 5,633,015, as a foundational patent in the DPP-4 inhibitor space, had a significant impact on the pharmaceutical industry by:
- Establishing Early Protection: It provided SmithKline Beecham with a broad intellectual property shield for a novel class of antidiabetic agents, allowing them to invest in research and development with a degree of market exclusivity.
- Enabling Further Research: The patent's broad claims encouraged other researchers to explore variations within the claimed genus, leading to the discovery and development of numerous DPP-4 inhibitors by other companies.
- Defining a Therapeutic Area: It played a role in defining and advancing the therapeutic area of DPP-4 inhibition for diabetes treatment, contributing to the development of a major class of oral antidiabetic medications.
- Facilitating Competition (Post-Expiration): Its expiration has paved the way for generic versions of early-generation DPP-4 inhibitors that fall squarely within its claims, increasing access and reducing treatment costs for patients.
While SmithKline Beecham may not have brought a blockbuster drug directly derived from this specific patent to market, the intellectual property established by this patent was critical in shaping the competitive landscape and driving innovation in the field of DPP-4 inhibition.
Key Takeaways
- U.S. Patent 5,633,015 claimed a broad genus of substituted 3-aminopyrrolidine compounds as DPP-4 inhibitors for treating diabetes.
- The patent expired on November 19, 2014, removing its direct protection.
- The claims covered a wide chemical space, enabling further research and development in the DPP-4 inhibitor class.
- The patent's expiration facilitates generic market entry for compounds within its scope, but other overlapping patents for specific molecules, formulations, or uses may still be in effect.
- The DPP-4 inhibitor landscape is complex, with multiple companies holding patents on various drugs within this class.
Frequently Asked Questions
1. Are there any drugs currently on the market that are directly covered by the expired claims of U.S. Patent 5,633,015?
Yes, there could be. The patent claimed a broad genus. While specific compounds derived from this patent might not have become blockbuster drugs for the original assignee, generic versions of early DPP-4 inhibitors falling within this broad chemical scope would have been covered by its claims prior to expiration. Post-expiration, these generic versions are no longer subject to this specific patent's restriction.
2. Does the expiration of U.S. Patent 5,633,015 mean that all DPP-4 inhibitors are now generic?
No, absolutely not. This patent covers a specific genus. Many later-developed DPP-4 inhibitors have distinct chemical structures that were not covered by this expired patent. These newer drugs are protected by their own patents, which may still be in force, and their generic availability depends on the expiration of those specific, later-expiring patents.
3. What is the significance of R1, R2, and R3 substituents in the patent's claims?
These substituents are crucial for defining the specific chemical entities within the claimed genus and for imparting the desired pharmacological activity, namely the inhibition of DPP-4. The variations in R1, R2, and R3 are what allow the patent to claim a broad range of potential molecules while still targeting the enzyme's active site.
4. What is the primary therapeutic target of the compounds claimed in this patent?
The primary therapeutic target is the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of this enzyme increases the levels of incretin hormones, leading to improved glycemic control in patients with diabetes.
5. Is it possible for another company to develop and patent a compound that falls within the scope of U.S. Patent 5,633,015's claims today?
No, it is not possible to obtain a new patent on a compound that is covered by the claims of an already expired patent. The claims of U.S. Patent 5,633,015, having expired in 2014, are now in the public domain. Any compound falling within those claims is considered prior art, and new patents cannot be granted for subject matter that is no longer novel or is already publicly known or available.
Citations
[1] SmithKline Beecham P.L.C. (1997). Substituted 3-aminopyrrolidines. U.S. Patent 5,633,015. Washington, DC: U.S. Patent and Trademark Office.
